酶法测定糖化白蛋白及其临床意义

目的评价酶法检测糖化白蛋白(GA)及临床意义.方法检测56名健康者血清GA水平,建立参考范围;检测所有试验者血清丙氨酸转氨酶(ALT)、天门冬氨酸转氨酶(AST)、尿素(Urea)、肌酐(Cr)、血脂[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]、空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c),统计GA与上述指标间的相关性.用GA高值血清和低值血清评估Lucica GA-L试剂盒的精密度及其线性.结果健康人群GA值为(14.35±2.00)%;GA与血清ALT、AST、Urea、Cr、TC、TG、HDL-C和LDL-C的相关系数(r)分别为0.010、0.012、0.003、0.061、-0.039、0.026、-0.038和-0.051,与FPG、2hPG、HbA1c的r分别为0.818、0.803和0.854,HbA1c与FPG、2hPG的r为0.845和0.820.健康者、临界者和糖尿病(DM)患者间GA差异有显著性(P<0.001).该法批内变异系数(CV)<2%,批间CV<5%,线性测定r=0.999 6;结论酶法检测GA有良好的精密度和稀释直线性,且不受血清ALT、AST、Urea及血脂水平的影响,与HbA1c一样能很好的反映FPG和2hPG水平,适用于监测高危人群和DM患者近期整体血糖水平.     

酶法测定糖化白蛋白及其临床意义

目的评价酶法检测糖化白蛋白(GA)及临床意义。方法检测56名健康者血清GA水平,建立参考范围;检测所有试验者血清丙氨酸转氨酶(ALT)、天门冬氨酸转氨酶(AST)、尿素(Urea)、肌酐(Cr)、血脂[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]、空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1 c),统计GA与上述指标间的相关性。用GA高值血清和低值血清评估Luc ica GA-L试剂盒的精密度及其线性。结果健康人群GA值为(14.35±2.00)%;GA与血清ALT、AST、U-rea、Cr、TC、TG、HDL-C和LDL-C的相关系数(r)分别为0.010、0.012、0.003、0.061、-0.039、0.026、-0.038和-0.051,与FPG、2hPG、HbA1 c的r分别为0.818、0.803和0.854,HbA1 c与FPG、2hPG的r为0.845和0.820。健康者、临界者和糖尿病(DM)患者间GA差异有显著性(P<0.001)。该法批内变异系数(CV)<2%,批间CV<5%,线性测定r=0.999 6;结论酶法检测GA有良好的精密度和稀释直线性,且不受血清ALT、AST、Urea及血脂水平的影响,与HbA1 c一样能很好的反映FPG和2hPG水平,适用于监测高危人群和DM患者近期整体血糖水平。     

糖化血红蛋白与血糖、血脂关系的探讨

目的 探讨2型糖尿病患者(DM)和糖调节受损者(IGT)糖化血红蛋白(HbA1c)与空腹血糖(FBG)、餐后2 h血糖(2 hBG)、血脂的相关性.方法 检测健康对照组(100例)、DM组(95例)、IGT组(77例)HbA1c、FBG、2 hBG、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)等,对结果进行t检验及相关性分析.结果 DM组HbA1c、FBG、2 hBG、TG、TC、LDL-C均显著高于健康对照组(P<0.01),HDL-C低于健康对照组(P<0.01),HbA1c与FBG、2 hBG呈显著正相关(r=0.95、0.62),与TG、TC、LDL-C有平行升高的趋势,与HDL-C呈负相关.DM组HbA1c、FBG和2 hBG水平与IGT组比较,差异有统计学意义(P<0.01),血脂水平差异无统计学意义(P>0.05).结论 HbA1c与血糖、血脂联合检测对糖尿病的预防、诊断、病情控制及并发症的防治有重要的临床意义.     

酶法测定糖化白蛋白的方法学评价及其与糖尿病诊断的相关性研究

目的对酶法测定糖化白蛋白(GA)进行方法学评价,验证其作为临床常规方法的各项性能指标。研究糖尿病患者糖化血红蛋白(HbA1c)和GA的相关性,为糖尿病早期诊断和治疗效果监测提供更好的方法。方法按美国临床实验室标准化协会(CLSI)EP10-A3文件对酶法测定GA的精密度、线性、偏差、互染率、漂移性进行评价。测定336例糖尿病患者GA和HbA1c浓度,研究其变化并进行相关性分析。根据美国糖尿病学会(ADA)标准(HbA1c7%为血糖控制良好、7%~8%为血糖控制一般、8%为血糖控制不佳),采用受试者工作特征(ROC)曲线确定GA/HbA1c比值评估血糖控制程度的临界值。结果酶法测定GA的总平均不精密度为1.62%,平均偏差为7.58%,截距、斜率、非线性、互染率、漂移性均可接受;非线性参数检测高值存在正向偏移,需要进行进一步观察以确认方法的线性性能,但对临床诊断不会带来影响。GA与HbA1c诊断糖尿病的一致性较好,为88.1%;两者相关系数(r)为0.879(P0.01)。ROC曲线显示GA/HbA1c比值评估血糖控制程度的最佳临界值为2.60,敏感性为86.8%、特异性为70.1%;如GA/HbA1c比值2.60,可认为血糖控制不佳。结论酶法测定GA的方法学性能符合常规检测质量标准。GA可用于糖尿病的诊断和疗效评估。GA/HbA1c比值可作为监测血糖控制的补充指标。     

血糖达标与糖化血红蛋白达标关系的临床研究

目的分析空腹血糖(FBG)达标和餐后2小时血糖(P2hBG)达标对糖化血红蛋白(HbA1c)的影响,为临床治疗提供指导。方法对300例门诊就诊2型糖尿病患者同时检测FBG、P2hBG和HbA1c,分析FBG达标(≤6.1mmol/L)、P2hBG达标(≤8.0mmol/L)与HbA1c达标(≤6.5%或7.0%)三者间的关系。结果(1)300例患者中,HbA1c≤6.5%和7.0%分别为72例和132例,占24.0%和44.0%;(2)FBG达标(FPG<6.1mmol/L)66例中,HbA1c≤6.5%达标率为53.0%,HbA1c≤7%的达标率为68.2%;(3)P2hBG达标(<8mmol/L)共49例中,HbA1c≤6.5%达标率为91.8%;HbA1c≤7%达标率为95.9%;(4)FBG和P2hBG均达标18例中,HbA1c≤6.5%达标率为94.4%;HbA1c≤7%达标率为100%。结论多数2型糖尿病患者血糖控制不理想,同时关注空腹血糖和餐后血糖,有助促进HbA1c更好达标。     

糖化血清蛋白和糖化血红蛋白联合检测在糖尿病诊断中的应用价值

目的评估糖化血清蛋白(GA)和糖化血红蛋白(HbA1c)检测在糖尿病诊断中的应用价值。方法该院内分泌科收治的糖尿病患者224例纳入糖尿病组,并选取238例健康人纳入对照组。2组研究对象均行口服葡萄糖耐量试验(OGTT)、GA、HbA1c检测,结果进行比较,并应用受试者工作特征(ROC)曲线评价二者对糖尿病的诊断性能。结果糖尿病组的OGTT、GA、HbA1c检测结果均高于对照组,差异均有统计学意义(P0.05)。糖尿病组的HbA1c与空腹血糖(FPG)、2h血糖均呈正相关(r=0.516、0.427,P0.05);GA与FPG、2h血糖呈正相关(r=0.527、0.449,P0.05);FPG与2h血糖呈显著正相关(r=0.462,P0.05);HbA1c与GA呈显著正相关(r=0.884,P0.05)。GA敏感度(85%)高于HbA1c敏感度(76%);HbA1c特异度(83%)高于GA特异度(75%)。GA、HbA1c与OGTT联合作ROC曲线,GA和HbA1c敏感度、特异度和预测概率分别为76%、72%、78%,71%、77%、81%;二者联合检测的敏感度、特异度、预测概率分别为77%、77%、76%。结论 GA和HbA1c联合检测在糖尿病诊断中具有重要的应用价值。     

2型糖尿病患者血浆甘露聚糖结合凝集素与血糖糖化血红蛋白的相关性分析

目的探讨2型糖尿病(T2DM)患者血浆甘露聚糖结合凝集素(MBL)水平及其与血糖、糖化血红蛋白(HbA1c)的关系。方法选取T2DM患者及健康人各60例,测定血浆MBL、空腹血糖(FPG)和HbA1c水平,观察MBL水平变化及与FPG、HbA1c的关系。结果 T2DM患者血浆MBL、FPG、HbA1c水平均高于健康对照组,差异有统计学意义(P0.01);Pearson相关性分析显示,血浆MBL水平与HbA1c呈明显正相关(r=0.257,P=0.047)。结论 MBL在T2DM患者血浆中明显增高,可能参与了T2DM的发病过程,检测MBL对T2DM的诊断和预后具有潜在的临床价值。     

胶乳凝集法测定糖化血红蛋白及其在2型糖尿病初诊中的应用

目的探讨胶乳凝集法测定糖化血红蛋白(HbA1c)及其在2型糖尿病(T2DM)初诊中的应用价值。方法选择以往未诊断过糖尿病(DM)和进行相应治疗的志愿者882例,受检者10h内无热量摄入,测定HbA1c、空腹血糖(FPG),餐后2h血糖(2hPG)和行口服葡萄糖耐量试验(OGTT)。结果 218例T2DM患者HbA1c显著高于空腹血糖受损(IFG)、糖耐量受损(IGT)及血糖试验正常(NGT)者(P<0.01);用ROC曲线法得到HbA1c临床诊断界值为6.4%,ROC曲线下面积为0.886,采用HbA1c≥6.4%判断T2DM时,其敏感性为77.5%,特异性为95.0%;以HbA1c≥6.4%检出2hPG≥11.1mmol/L的敏感率为77.0%,漏诊率为23.0%。结论 HbA1c诊断敏感性和诊断性能优于FPG,胶乳凝集法测定HbA1c稳定性好、精确度高,能进行自动分析,可取代FPG用于临床DM筛查和初诊。     

糖化血红蛋白对糖尿病的诊断价值

摘要：目的：探讨糖化血红蛋白（HbA1c）在糖尿病(DM)诊断中的应用价值。 方法：随机选择DM初筛患者535例,均行口服葡萄糖耐量试验（OGTT）,用高效液相色谱法检测HbA1c水平。根据OGTT结果把受试者分为糖耐量正常（NGT）组、血糖调节受损(IGR)组和糖尿病(DM)组,NGT组和IGR组并称为非糖尿病组(non-DM)。用ROC曲线分析HbA1c、空腹血糖（FPG）诊断DM及IGR的能力。 结果：DM组患者、FPG、餐后2 h血糖（2h PG）及HbA1c均显著高于其他组(P均＜0.01);上述指标IGR组亦显著高于NGT组(P均＜0.01)。DM组男性患者显著多于女性(P＜0.01)。HbA1c 的cut off值为6.1%时,诊断DM的ROC曲线下面积（AUC^ROC）为0.849,敏感性为79.1%,特异性为78.4%,与7.0 mmol/L FPG的诊断能力无显著性差异（P>0.05）。2者联合应用显著提高诊断能力,AUC^ROC=0.885,敏感性为75.0%,特异性为88.0%。以HbA1c 5.7%为cut-off值,诊断IGR（AUCV=0.66）能力显著低于FPG（AUC^ROC=0.787）,P<0.01。 结论:HbA1c的cut off值为6.1%时可用于诊断DM,与7.0 mmol/L FPG 联合应用可增加诊断DM的能力,但5.7% HbA1c对IGR的筛查能力较弱,不及5.6 mmol/L FPG。     

糖化白蛋白、糖化血红蛋白及其比值在新诊断2型糖尿病患者降糖过程中的变化

目的探讨糖化白蛋白(GA)、糖化血红蛋白(HbA1c)及其比值(GA/HbA1c)在新诊断2型糖尿病(T2DM)患者降糖过程中变化。方法以70例内分泌科门诊和住院的新诊断T2DM患者为研究对象。所有患者均单服二甲双胍治疗24周,并于服药前、每服药4周后取空腹静脉血检测GA和HbA1c。结果GA在第8周时从基础值(26.1±8.3)%下降至最低值(17.3±4.5)%,差异有统计学意义(P0.01),HbA1c则在第16周时从基础值(10.1±2.4)%下降至最低值(7.5±1.0)%,差异有统计学意义(P0.01)。GA/HbA1c比值在第8周时从基础值(2.58±0.35)下降为最低值(2.06±0.24),差异有统计学意义(P0.001),后在第16周时又上升为(2.31±0.31),但仍低于基础值,差异有统计学意义(P0.01)。整个治疗期间GA/HbA1c值的变化(△GA/HbA1c)与基础HbA1c(r=-0.657,P=0.008)、GA(r=-0.702,P=0.002)呈负相关而与△GA呈正相关(r=0.813,P0.001),与△HbA1c无相关性。结论在新诊断的T2DM患者降糖过程中,GA/HbA1c可能比GA或HbA1c更能反映血糖控制效果。     

Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma

OBJECTIVE: The measurement of plasma glycated albumin is particularly useful in the short-middle term monitoring of glycometabolic control in diabetics. The aim of this work is to evaluate a new enzymatic method for the measurement of glycated albumin in plasma, with particular attention to some selected cases and comparison with other relevant tests (fasting plasma glucose, after glucose load, fructosamine, glycated hemoglobin). DESIGN AND METHODS: We have performed a multicenter study by which sample collection was performed in three different centers (Milano, Padova and Cagliari) and serum samples, frozen at -80 degrees C, were then delivered under dry ice to the centralized laboratory in Milano. Glycated plasma albumin was measured with reagents from Asahi Kasei Pharma (Lucica GA-L enzymatic assay; AKP, Tokyo, Japan) on a Modular P Roche system. Fructosamine was assessed by a Roche method and HbA(1c) (measured separately in the three centers on fresh EDTA blood) by DCCT-aligned HPLC systems. We have investigated 50 type 2 diabetics, 26 subjects with gestational diabetes, 35 subjects with thalassemia major, 10 subjects with cirrhosis, 23 patients with end-stage renal disease subjected to dialysis treatment and 32 healthy adult control subjects. RESULTS: The main analytical performance characteristics of the new GA test were the following: (a) the within-assay reproducibility was between 3.0 and 3.9% (in terms of GA% CV, measured on 2 serum pools and 2 control materials at normal and pathological glycated albumin levels); (b) the between-assays reproducibility was from 2.8 to 4.1%; (c) the linearity was tested in the interval between 13 and 36% and found acceptable (r(2)=0.9932). Concerning the clinical utility of the new test, we have evaluated the relationships between GA, HbA(1c), fructosamine and fasting and post-prandial glucose in several patients, as well as the changes in the above mentioned parameters in a sub-group of type 2 diabetic patients for 18 weeks as they progressed from severe hyperglycemia (HbA(1c) >or=10.0%) toward a better glycemic control. The correlations between glycated albumin and HbA(1c) were as follows: (a) type 2 diabetics: r(2)=0.483 (good glycemic control), r(2)=0.577 (poor control); (b) diabetic patients under dialysis: r(2)=0.480; (c) liver disease: r(2)=0.186; (d) transfused non-diabetics with thalassemia: r(2)=0.004. Glycated albumin, as well as HbA(1c) and fructosamine, was of little value in the study of women with gestational diabetes, mainly because of the very limited glucose fluctuations in this particular category of subjects. In 11 type 2 diabetic patients under poor metabolic control, GA was better correlated with fasting plasma glucose then HbA(1c) (r(2)=0.555 vs. 0.291, respectively), and decreased more rapidly than HbA(1c) during intensive insulin therapy. CONCLUSIONS: The experience we have acquired with the new enzymatic test demonstrates its reproducibility and robustness. We confirm that plasma glycated albumin is better related to fasting plasma glucose with respect to HbA(1c). Moreover, glycated albumin is more sensitive than HbA(1c) with regard to short-term variations of glycemic control during treatment of diabetic patients. This test is also very appropriate when the interpretation of HbA(1c) is critical.     

Measurement of glycated albumin in serum and plasma by LC-MS/MS

Background Diagnosis of diabetes and monitoring of long-term blood sugar are preferably done by measurement of glycated hemoglobin (HbA1c). Diabetic patients with end stage renal disease (ESRD) may have short-lived red blood cells due to hemodialysis (HD), and thus higher turnover of hemoglobin. The level of glycated hemoglobin (HbA1c) may be lower than expected for these patients, even at increased blood glucose, possibly making glycated albumin (GA) measurement a better alternative. Methods The percentage of GA was measured by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Fast and efficient trypsin digestion of proteins in diluted serum or plasma resulted in a high number of proteotypic peptides from albumin, including KQTALVELVK which was detected both glycated and non-glycated by multiple reaction monitoring (MRM). The percentage of GA was estimated by neat peak area response of glycated peptide divided by the sum of glycated and non-glycated peptide. Results Acceptable method reproducibility (6% CV), repeatability (2–6% CV), limit of quantification (0.75% GA), linearity (R²?=?0.999) and recovery (79?±?9%) was achieved without using calibration or isotope-labeled internal standard. GA was strongly correlated with HbA1c (r?=?0.84) for patients without ESRD. The average ratio of GA/HbA1c was significantly higher (p?=?0.0021) for ESRD patients (1.84?±?0.38, n?=?62) compared to other patients (1.67?±?0.28, n?=?225). Conclusion GA measurement by detecting glycation in KQTALVELVK with LC-MS/MS seems to be a useful supplement to HbA1c for detecting increased blood glucose in diabetic patients with ESRD.     

Quantification of nonenzymically glycated albumin and total serum protein by affinity chromatography

We have evaluated an affinity-chromatographic procedure for determination of glycated albumin (GA) and glycated total serum protein (GSP). Recovery of these analytes was inversely related to free glucose concentration, thus necessitating removal of free glucose. For this we used molecular-exclusion chromatography on G-25 Sephadex, or dialysis, the latter procedure resulting in significantly (p less than 0.05) lower concentrations of GSP and GA. Total protein concentration and percent glycation are also inversely related, and so protein concentrations must be standardized before the assay. Within- and between-run CVs for both GSP and GA were less than 6.5 and 18%, respectively, the determination of GA being generally the more precise of the two. Labile glycated fractions, lipemia, icterus, hemolysis, and type of anticoagulant did not affect the results, but assay temperature did. Diabetic subjects showed substantially higher concentrations of GA and GSP than did normal subjects. Because of the life span of these analytes in circulation, their measurement may provide a short-term index of glycemic control.     

Blood glycated haemoglobin, serum fructosamine, serum glycated albumin and serum glycated total protein as measures of glycaemia in diabetes mellitus.

Blood glycated haemoglobin (HbAlc), serum fructosamine (FA), serum glycated albumin (GA), and serum glycated total protein (GTP) were determined in 61 subjects (19 pregnant women with gestational diabetes, 24 pregnant women with insulin-dependent diabetes mellitus [IDDM] and 18 nonpregnant subjects with IDDM). FA, GA, and GTP correlated with HbAlc similarly (r = 0.791, 0.816, and 0.794, respectively, p < 0.001). In a subgroup of 22 subjects data on blood glucose home monitoring was recorded and used for calculating mean blood glucose as an index of average glycaemia preceding sampling of the glycation products. Mean blood glucose levels preceding sampling of HbAlc by 2 months and FA, GA, or GTP by three weeks correlated significantly with HbAlc (r = 0.668, p < 0.001) and GA (r = 0.441, p < 0.05) whereas no significant correlation was found between mean blood glucose and FA (r = 0.003) or GTP (r = 0.252). In conclusion, such methods which measure specifically the non-enzymatic glycation of a single species of protein (i.e. FPLC for HbAlc and affinity chromatography for GA) are to be preferred for assessing glycaemia.     

糖化白蛋白在妊娠期糖尿病筛查及诊断中的价值探讨

目的：评价糖化白蛋白（GA）测定在妊娠期糖尿病诊断中的价值。方法选取2011年9月-2012年3月在我院进行产前检查并于24-28周接受50 g 葡萄糖糖尿病筛查结果异常的孕妇160例,以第7版《妇产科学》的诊断标准分为糖耐量正常组,糖耐量受损组,糖尿病组。对三组的空腹血糖（FPG）,糖化血红蛋白（HbA1c）,糖化白蛋白（GA）等进行对比研究,评价 GA 在妊娠期糖尿病诊断中的价值。结果三组的 FPG、HbA1c、GA 结果有显著性差异,三组中 GA 与 HbA1c 均具有相关性。结论糖化白蛋白（GA）的测定对妊娠糖尿病病变程度的变化具有提示作用,对妊娠期糖尿病的筛查和诊断具有价值,可作为临床应用。     

Blood glycated haemoglobin,serum fructosamine,serum glycated albumin and serum glycated total protein as measures of glycaemia in diabetes mellitus

Blood glycated haemoglobin (HbAlc), serum fructosamine (FA), serum glycated albumin (GA), and serum glycated total protein (GTP) were determined in 61 subjects (19 pregnant women with gestational diabetes, 24 pregnant women with insulin-dependent diabetes mellitus [IDDM] and 18 non-pregnant subjects with IDDM). FA, GA, and GTP correlated with HbAlc similarly (r=0.791, 0.816, and 0.794, respectively, p < 0.001). In a subgroup of 22 subjects data on blood glucose home monitoring was recorded and used for calculating mean blood glucose as an index of average glycaemia preceding sampling of the glycation products. Mean blood glucose levels preceding sampling of HbAlc by 2 months and FA, GA, or GTP by three weeks correlated significantly with HbAlc (r=0.668, p < 0.001) and GA (r=0.441, p < 0.05) whereas no significant correlation was found between mean blood glucose and FA (r=0.003) or GTP (r=0.252). In conclusion, such methods which measure specifically the non-enzymatic glycation of a single species of protein (i.e. FPLC for HbAlc and affinity chromatography for GA) are to be preferred for assessing glycaemia.     

探讨糖化清蛋白在糖尿病中的诊断价值及诊断切点

目的评估糖化清蛋白(GA)在糖尿病中的诊断价值及诊断切点,比较GA、糖化血红蛋白(HbA1c)、空腹血糖(FPG)及餐后2h血糖(2hPG)对糖尿病的诊断效能。方法选取470例南京医科大学第一附属医院门诊就诊的疑似糖尿病患者,排除严重肝肾疾病者,检测口服葡萄糖耐量试验(OGTT)、GA、HbA1c。采用SPSS21.0软件进行统计,采用ROC曲线分析各指标对糖尿病的诊断价值并探讨诊断切点。结果 GA对于血糖调节受损(IGR)诊断的ROC曲线下面积为0.693,与HbA1c(0.692)相近;而以最佳截断点14.57%作为诊断切点,GA对IGR诊断的敏感度和特异度分别为0.79和0.55;GA对于糖尿病诊断的ROC曲线下面积为0.911(低于2hPG的0.994和HbA1c的0.948),而以最佳截断点17.50%作为诊断切点,其敏感度和特异度分别为0.89和0.83,其敏感度略高于HbA1c(0.85)。结论 GA对于IGR诊断有一定价值,对于糖尿病诊断有较高价值,可作为2hPG和HbA1c的有效补充。     

溴甲酚绿法与溴甲酚紫法对血清糖化清蛋白水平检测的影响

目的　探讨溴甲酚绿（bromocresol green, BCG）法和溴甲酚紫（bromocresol purple, BCP）法测定血清清蛋白 （albumin, Alb）对糖化清蛋白(glycated albumin, GA) 的结果影响。方法　回顾性收集2018 年1~12 月于西安交通大学 第一附属医院就诊患者溴甲酚绿法清蛋白（AlbBCG）和溴甲酚紫法清蛋白（AlbBCP）的检验数据,分别计算溴甲酚绿法 糖化清蛋白（GABCG）和溴甲酚紫法糖化清蛋白（GABCP）,并比较两种方法所测得的结果是否存在差异。结果　随着 患者体内Alb 水平的降低,两种方法测得的Alb 值和GA 值出现显著性差异。当Alb<35g/L 时,BCG 法比BCP 法Alb 测定的Alb 值略高,约高2.18g/L;BCG 法比BCP 法测定的GA 值略低,约低1.01%。当Alb ≥ 35g/L 时, 两种方法测 定GA 值无显著统计学差异（t=2.0,P=0.05）。两种检测方法计算GA 结果一致性均较好,但当Alb ≥ 35g/L 时, 两种 方法对于GA 检测一致性更高。结论　在糖化清蛋白检测中,若患者血清中Alb 较低,BCG 法非特异性反应增加,导 致所测的GA 值低于BCP 法所测得的GA 值,可能低估患者GA 水平。因此,BCP 法更适合检测伴有低蛋白血症糖尿 病患者的GA 值。     

两种类型标本糖化清蛋白检测结果的评估

目的评估静脉血浆和血清标本糖化清蛋白(GA)检测结果之间的差异。方法选取2019年1月于该院就诊的患者75例,无特定的排除标准,收集其乙二胺四乙酸二钾(EDTA-K 2)抗凝静脉血和无添加剂静脉血标本各1管,分离出血浆和血清,检测清蛋白(ALB)、GA(%)水平,应用统计学方法分析分别使用血浆标本和血清标本检测GA(%)的偏倚。结果ALB水平为26.3~47.5 g/L,GA(%)水平为10.5%~20.0%,静脉血浆与血清的ALB水平差异有统计学意义(P<0.05),GA(%)水平差异无统计学意义(P>0.05)。呈偏态分布的血浆与血清GA(%)相对偏差的中位数为-1.01%,Passing-Bablok回归模型拟合得到的回归方程为Y=-1.882+1.126 X,将GA(%)诊断切点14.3%和16.3%代入回归方程,偏倚分别为-0.15%和1.41%,均小于生物学变异研究的预期偏倚范围(±2.9%)。结论GA(%)的水平在10.5%~20.0%时,EDTA-K 2抗凝静脉血浆与无添加剂静脉血清标本用于GA检测的差异小,其偏倚在临床可接受范围内,均可在临床使用。